LLY vs NVS
Eli Lilly and Company vs Novartis AG — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
56
Buy
VS
| Metric | LLY | NVS |
|---|
| AI Score |
56
|
61
|
| Price |
$1,249.69
|
$159.78
|
| P/E Ratio |
41.81×
|
23.98×
|
| ROE |
77.8%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
74.3%
|
| Debt / Equity |
1.62×
|
1.18×
|
| Dividend Yield |
0.5%
|
2.9%
|
| RSI (14) |
59.0
|
57.9
|
| Beta |
0.506
|
0.462
|
| Expected Upside |
+0.1%
|
+1.6%
|
AI Committee View
Current Innellis committee reasoning for LLY versus NVS.
NVS leads by 5 points.
NVS scores 61/100 (Buy) versus LLY at 56/100 (Buy).
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
NVS Committee View
60% agreement
5 analysts
Positive signals support the current rating — price structure making higher highs and higher lows. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 29.9% shows genuine earnings power backing the valuation — Value
- Dividend yield of 3.7% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 5.6x prices in significant intangible value — Value
- EPS declining -3.5% YoY despite any revenue growth — Growth